Moleculin Biotech
MBRX
27 hedge funds and large institutions have $5.16M invested in Moleculin Biotech in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
400% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
42% more funds holding
Funds holding: 19 → 27 (+8)
0% more ownership
Funds ownership: 0% → 0% (+0%)
3% less capital invested
Capital invested by funds: $5.31M → $5.16M (-$147K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$245K |
| 2 |
Renaissance Technologies
New York
|
+$116K |
| 3 |
Jane Street
New York
|
+$43.9K |
| 4 |
Bank of New York Mellon
New York
|
+$41.3K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$33.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$87.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20K |
| 3 |
BlackRock
New York
|
-$7.75K |
| 4 |
ACS
Archford Capital Strategies
Swansea,
Illinois
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
APA
26
American Portfolios Advisors
Holbrook,
New York
| $2.22K | – | – | – |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$2.58K | +1 | New |
|
28
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
GRP
29
Global Retirement Partners
San Rafael,
California
| $1K | – | – | – |
|
|
PWMG
30
Prestige Wealth Management Group
Flemington,
New Jersey
| $1K | – | – | – |
|
|
TRCT
31
Tower Research Capital (TRC)
New York
| $1K | – | – | – |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$20K | -7 | Closed |
|
|
ACS
33
Archford Capital Strategies
Swansea,
Illinois
| – | -$4K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q3 2019 in Review
27 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2019, worth a combined $5.16M — down 2.8% from $5.31M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MBRX positions and 2 closed out — a net gain of 8 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $245K. The largest seller was Vanguard Group, cutting an estimated $87.8K.
- 27 institutional investors held Moleculin Biotech (MBRX) as of Q3 2019, up from 19 in Q2 2019.
- Funds reported $5.16M of Moleculin Biotech stock for Q3 2019, down 2.8% quarter-over-quarter.
- 10 funds opened new Moleculin Biotech positions in Q3 2019 and 2 closed out, a net change of +8 holders.
- The largest Moleculin Biotech buyer in Q3 2019 was Millennium Management, an estimated $245K added.
- The largest Moleculin Biotech seller in Q3 2019 was Vanguard Group, an estimated $87.8K sold.
Based on aggregated 13F filings for Q3 2019.